Jbm (Healthcare) Ltd
HKEX:2161

Watchlist Manager
Jbm (Healthcare) Ltd Logo
Jbm (Healthcare) Ltd
HKEX:2161
Watchlist
Price: 2.7 HKD -0.37% Market Closed
Market Cap: 2.2B HKD

Jbm (Healthcare) Ltd
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Jbm (Healthcare) Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Jbm (Healthcare) Ltd
HKEX:2161
Cash & Cash Equivalents
HK$205.8m
CAGR 3-Years
43%
CAGR 5-Years
23%
CAGR 10-Years
N/A
G
Grand Pharmaceutical Group Ltd
HKEX:512
Cash & Cash Equivalents
HK$479.1m
CAGR 3-Years
-23%
CAGR 5-Years
-19%
CAGR 10-Years
-5%
U
United Laboratories International Holdings Ltd
HKEX:3933
Cash & Cash Equivalents
ÂĄ9B
CAGR 3-Years
31%
CAGR 5-Years
24%
CAGR 10-Years
29%
Sino Biopharmaceutical Ltd
HKEX:1177
Cash & Cash Equivalents
ÂĄ11.2B
CAGR 3-Years
23%
CAGR 5-Years
-7%
CAGR 10-Years
17%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Cash & Cash Equivalents
HK$17.7B
CAGR 3-Years
-1%
CAGR 5-Years
6%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Cash & Cash Equivalents
$110.7m
CAGR 3-Years
-38%
CAGR 5-Years
17%
CAGR 10-Years
9%
No Stocks Found

Jbm (Healthcare) Ltd
Glance View

Market Cap
2.2B HKD
Industry
Pharmaceuticals

JBM (Healthcare) Ltd. functions as an investment holding company. The company employs 274 full-time employees The company went IPO on 2021-02-05. The firm operates its business through three segments. The Proprietary Chinese Medicines segment mainly distributes over the counter (OTC) proprietary Chinese medicines and concentrated Chinese medicine granule (CCMG) products. The Consumer Healthcare Products segment primarily distributes proprietary medicines in the form of OTC. The Health and Wellness Products segment sales and distributes health and wellness products. The firm operates business in domestic and overseas markets such as Southeast Asia, Europe, and North America.

Intrinsic Value
4.35 HKD
Undervaluation 38%
Intrinsic Value
Price

See Also

What is Jbm (Healthcare) Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
205.8m HKD

Based on the financial report for Mar 31, 2025, Jbm (Healthcare) Ltd's Cash & Cash Equivalents amounts to 205.8m HKD.

What is Jbm (Healthcare) Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
23%

Over the last year, the Cash & Cash Equivalents growth was 46%. The average annual Cash & Cash Equivalents growth rates for Jbm (Healthcare) Ltd have been 43% over the past three years , 23% over the past five years .

Back to Top